United Therapeutics Corporation (UTH.F)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. | Founder, Chairman & CEO | 4.96M | 52.34M | 1955 |
| Mr. Michael I. Benkowitz | President & COO | 2.64M | 7.3M | 1972 |
| Mr. James C. Edgemond | CFO & Treasurer | 1.87M | 1.39M | 1968 |
| Mr. Paul A. Mahon J.D. | Executive VP, General Counsel & Corporate Secretary | 2.15M | 12.31M | 1964 |
| Mr. Dewey Steadman C.F.A. | Head of Investor Relations | -- | -- | -- |
| Ms. Holly Hobson | Associate Vice President of Human Resources | -- | -- | -- |
| Kevin T. Gray | Senior Vice President of Strategic Operations & Logistics | -- | -- | -- |
| Mr. Patrick Poisson | Executive VP of Technical Operations | -- | -- | 1968 |
| Dr. Leigh Peterson | Executive Vice President of Product Development & Xenotransplantation | -- | -- | -- |
| Mr. Gil Golden | Senior VP & Chief Medical Officer | -- | -- | -- |
United Therapeutics Corporation
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 1,168
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Corporate Governance
Recent Events
Recent Events Information Not Available